NCT04789057View on ClinicalTrials.gov

Atorvastatin Effect on Reduction of COPD Exacerbations

PHASE4RecruitingINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

February 11, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

May 31, 2027

Conditions
CopdCOPD ExacerbationSmokingGene ExpressionAtorvastatin
Interventions
DRUG

Atorvastatin 40 Mg Oral Tablet

p.o., once daily

DRUG

Placebo

p.o., once daily

Trial Locations (1)

15-540

RECRUITING

Medical University Hospital, Bialystok

Sponsors
All Listed Sponsors
collaborator

Medical Research Agency, Poland

OTHER_GOV

lead

Medical University of Bialystok

OTHER

NCT04789057 - Atorvastatin Effect on Reduction of COPD Exacerbations | Biotech Hunter | Biotech Hunter